JayTee2328

Entry comments: Based on Stansbury's analyst and StockGumShoe recommendations. Regarding Obesity drug in late stage trial...FDA approval expect in NOV'20

Exit comments: It was a long wait but worth it!

4
000

Broker:Fidelity
DatePrice
Entry12/16/202225.99
Exit4/17/202331.04
  • Total Views303
  • Position Size200
  • Percentage19.43%
Copy and paste the following into your page or blog. If using WordPress, you must paste this in the HTML tab only:
JayTee2328
JayTee2328Mar 02, 21 12:09 PM

Analyst Actions: Morgan Stanley Adjusts Price Target on Rhythm Pharmaceuticals to $57 From $53, Maintains Overweight Rating

JayTee2328
JayTee2328Apr 10, 23 2:52 PM

4/10/23 sold 200 at end of 2022 for a tax loss offset...sitll hold 5.36 share and may buy more At <$17

Join now or log in to leave a comment